Dr. Den Discusses Bone-Targeting Agents in Prostate Cancer

Robert B. Den, MD
Published: Tuesday, Mar 20, 2018



Robert B. Den, MD, associate professor of radiation oncology, Thomas Jefferson University Hospital, discusses bone-targeting agents in prostate cancer.

About 90% of patients with prostate cancer who develop metastases will develop bone metastases. Zoledronic acid (Zometa), radium-223 dichloride (Xofigo), and denosumab (Xgeva) are agents designed to target the makeup of the bone. The bone is generally made up of calcium and phosphatase; zoledronic acid works through the phosphatase side, radium-223 works through the calcium side, and denosumab decreases the osteoclastic activity of the bone.

The bone is constantly on a balance beam, says Den, both building and destroying bone. This balance is based on the production of bone based on the osteoblasts, and the reduction of bone by the osteoclasts. While denosumab decreases the osteoclasts, radium-223 works as a calcium mimetic to cause uptake up radium into the bone, says Den. Thus, radium gets targeted toward areas of increased prostate cancer, he adds.


Robert B. Den, MD, associate professor of radiation oncology, Thomas Jefferson University Hospital, discusses bone-targeting agents in prostate cancer.

About 90% of patients with prostate cancer who develop metastases will develop bone metastases. Zoledronic acid (Zometa), radium-223 dichloride (Xofigo), and denosumab (Xgeva) are agents designed to target the makeup of the bone. The bone is generally made up of calcium and phosphatase; zoledronic acid works through the phosphatase side, radium-223 works through the calcium side, and denosumab decreases the osteoclastic activity of the bone.

The bone is constantly on a balance beam, says Den, both building and destroying bone. This balance is based on the production of bone based on the osteoblasts, and the reduction of bone by the osteoclasts. While denosumab decreases the osteoclasts, radium-223 works as a calcium mimetic to cause uptake up radium into the bone, says Den. Thus, radium gets targeted toward areas of increased prostate cancer, he adds.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x